TRV GP IV, LLC — Q2 2025 13F-HR

← TRV GP IV, LLC

Q2 2025 · 13F-HR

TRV GP IV, LLCholdings as filed

Filed 2025-08-08 · accession 0000950123-25-007372

$163.3M

Reported value

Positions

2025-06-30

Period end

View analyzed profile →PRO

The Brief · TRV GP IV, LLC · Q2 2025

AI · grounded in 13F

TRV GP IV, LLC established a new position in Tango Therapeutics, Inc. TNGX valued at $86.3M. The fund also initiated a position in Maze Therapeutics, Inc. MAZE for $74.5M. Additionally, the fund added Pliant Therapeutics, Inc. PLRX to its portfolio with a $2.5M investment.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
87583X109	TNGX	TANGO THERAPEUTICS, INC.	$86.3M	52.9%	16,859,075	Common	SOLE
578784100	MAZE	MAZE THERAPEUTICS, INC.	$74.5M	45.6%	6,073,958	Common	SOLE
729139105	PLRX	PLIANT THERAPEUTICS, INC.	$2.5M	1.51%	2,132,867	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.